TMEM180 contributes to SW480 human colorectal cancer cell proliferation through intra-cellular metabolic pathways.
MFSD13A
Metabolomics
Nitric oxide synthase
TMEM180
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
10
05
2021
revised:
19
07
2021
accepted:
21
07
2021
pubmed:
1
8
2021
medline:
1
8
2021
entrez:
31
7
2021
Statut:
ppublish
Résumé
TMEM180, a novel colon cancer-specific protein with a 12-transmembrane topology, is upregulated at low oxygen. Previously, we established a humanized monoclonal antibody against TMEM180 aimed at clinical trials. Prior to such trials, it is necessary to clarify the function of TMEM180 in cancer. To compare SW480 human colon cancer cells and their TMEM180-knockdown derivatives, we analyzed proliferation and oxygen consumption, and also performed phosphorylation proteomics, metabolomics, and next-generation sequencing (NGS). The preliminary results revealed that TMEM180 appeared to promote the growth of colon cancer but had almost no effect on oxygen consumption or expression of phosphorylated proteins. By contrast, glycolysis differed dramatically between SW480 and TMEM180-knockdown cells. The NGS analysis revealed that TMEM180 promotes enzyme expression in nitric oxide (NO) synthesis system, suggesting that it promotes glucose and glutamine metabolism, thereby contributing to cancer growth. Overall, the results of this study warrant further basic studies of TMEM180 molecule.
Identifiants
pubmed: 34332338
pii: S1936-5233(21)00178-9
doi: 10.1016/j.tranon.2021.101186
pmc: PMC8335657
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101186Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
Anim Nutr. 2016 Mar;2(1):12-17
pubmed: 29767008
Biochem Pharmacol. 2020 Jun;176:113769
pubmed: 31862448
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Mol Biosyst. 2011 Apr;7(4):1217-23
pubmed: 21258713
Anal Chem. 1996 Mar 1;68(5):850-8
pubmed: 8779443
PLoS One. 2009 Sep 15;4(9):e7033
pubmed: 19753307
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BMC Cancer. 2021 Mar 23;21(1):302
pubmed: 33757462
Histopathology. 2020 Mar;76(4):498-508
pubmed: 31596504
Cancer Sci. 2019 Feb;110(2):761-770
pubmed: 30537002
Electrophoresis. 1998 May;19(6):1036-45
pubmed: 9638950
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1093-100
pubmed: 24696726
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Biochem Biophys Res Commun. 2019 Dec 10;520(3):566-572
pubmed: 31615651
Oncotarget. 2016 Feb 2;7(5):5598-612
pubmed: 26734996
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Oncotarget. 2015 Apr 10;6(10):7619-31
pubmed: 25844758
Pharmacol Rev. 2006 Sep;58(3):488-520
pubmed: 16968949
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Endocr Rev. 2014 Apr;35(2):195-233
pubmed: 24311737
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
BMC Res Notes. 2019 Mar 13;12(1):133
pubmed: 30867032
J Clin Med. 2019 Mar 13;8(3):
pubmed: 30871151
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Mol Carcinog. 2019 Oct;58(10):1855-1862
pubmed: 31237042
Tumour Biol. 2014 Mar;35(3):1855-62
pubmed: 24096582
Mol Cancer. 2014 Mar 21;13:65
pubmed: 24650096